Understanding Doxorubicin Resistance in Lung and Breast Cancer Cells
Author Information
Author(s): G.J. Schuurhuis, T.H.M. van Heijningen, A. Cervantes, H.M. Pinedo, J.H.M. de Lange, H.G. Keizer, H.J. Broxterman, J.P.A. Baak, J. Lankelma
Primary Institution: The Free University and The Netherlands Cancer Institute
Hypothesis
Doxorubicin resistance in multidrug resistant tumor cells can be explained by changes in drug accumulation and efficacy.
Conclusion
Doxorubicin resistance in multidrug resistant cells is largely due to decreased drug accumulation and altered subcellular distribution.
Supporting Evidence
- Doxorubicin resistance factors can be largely explained by decreased amounts of drug at nuclear targets.
- N/C ratios were significantly lower in resistant cells compared to sensitive cells.
- Verapamil was shown to increase the efficacy of doxorubicin in resistant cells.
- Changes in drug distribution were observed in both P-glycoprotein positive and negative cells.
- Residual resistance levels were correlated with drug accumulation and efficacy.
- Complete reversal of resistance was associated with normalization of drug distribution.
- Different mechanisms of resistance were identified in P-glycoprotein positive and negative cells.
- Verapamil's effects were not solely due to increased drug accumulation.
Takeaway
Some cancer cells don't respond well to a drug called doxorubicin because the drug doesn't get to where it needs to work inside the cell. We found that changing how the drug moves inside the cell can help it work better.
Methodology
The study used a quantitative approach to analyze doxorubicin accumulation and efficacy in various cancer cell lines.
Limitations
The study may not account for all mechanisms of drug resistance beyond those investigated.
Want to read the original?
Access the complete publication on the publisher's website